Qualifying Therapeutic Discovery Project Grants The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant. The project descriptions below were extracted from the applicant certification forms as submitted. Alabama $3,708,304.65 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Molecular Heparan Sulfate Agenta Biotechnologies Delivery in Barrier Membranes $59,614.76 $184,864.48 Inc and Soft Tissue Wound Closure DELIVERY OF GROWTH- AGENTA FACTOR CO-RECEPTOR BIOTECHNOLOGIES HEPARAN SULFATE IN $169,808.39 $6,666.50 INC BONE GRAFT SUBSTITUTES FOR REPAIR BioCryst BCX4208 for Treatment of $244,479.25 Pharmaceuticals Inc Gout BioCryst Peramivir for Treatment of $244,479.25 Pharmaceuticals, Inc Influenza BioCryst Forodesine for Treatment of $244,479.25 Pharmaceuticals, Inc CLL and CTCL BioCryst BCX4161 for Treatment of $86,380.89 Pharmaceuticals, Inc. Hereditary Angioedema JAK Inhibitors for Treatment BioCryst of Psoriasis, Ankylosing $244,479.25 Pharmceuticals, Inc. Spondylitis, & Multiple Sclerosis Disease Diagnostic Panel Diatherix Laboratories, Development Utilizing the $244,479.25 Inc. TEM-PCR Method Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 EGEN-001 in Platinum- EGEN INC $244,479.25 Resistant Ovarian Cancer EGEN, INC. EGEN TheraSilence $244,479.25 Development of an Apparatus iCubate, Inc $244,479.25 for Performing am-PCR Phase 1, Open-label Syudy Evaluting the Safety of PNP Therapeutics Inc $244,479.25 Escalating Doses of Ad/PNP- F-araAMP SER-201 for the treatment of Serina Therapeutics, Inc $244,479.25 colorectal and ovarian cancer Development of an Vaxin Inc. Adenovirus-Vectored Nasal $244,479.25 Anthrax Vaccine Replication-Defective Adenovirus-Vectored Vaxin Inc. $161,175.00 $83,304.25 Influenza Vaccine Development Nanotechnology Enabled Vista Engineering Inc Temporomandibular Joint $29,059.63 $32,059.00 (TMJ) Prosthesis Development of sorptive nasal Volatile Analysis stent for diagnostic biomarker $23,600.00 $182,500.00 Corporation detection Arizona $7,503,090.80 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 AmpliMed Development of small-molecule $244,479.24 Corporation anti-cancer drugs NeuVax-adjuvant treatment for Apthera, Inc. $244,479.25 node positive breast cancer with Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 low to intermediate HER2 Development of Ultrasound Ardent Sound Inc. Therapy Device for Sebaceous $244,479.25 and Sweat Gland Treatment Ascalon IV Fenretinide $106,406.50 $138,072.74 International Inc Integrated platform for bioVidria, Inc. $47,799.50 $114,302.50 glycoform biomarker discovery TGEN COLLABORATION: BLUE HORSE GENETIC RISK FACTORS $179,589.50 $8,301.50 LABS, INC. FOR ALZHEIMER'S DISEASE (PHASE II) Oxidative stress markers in Blue Horse Labs, multiple matrices as biomarkers $7,160.00 $88,697.00 Inc. for disease Hematopoietic Stem Cell Therapy for HIV/AIDS Usifng Calimmune, Inc. $244,479.25 RNAi to Reduce Expression of CCR5 Cancer Prevention Eflornithine $189,893.77 $54,585.48 Pharmaceuticals Inc Capstone AZX100 for Idiopathic $78,150.00 $166,329.24 Therapeutics Corp Pulmonary Fibrosis (IPF) Cold Plasma Harmonic Cold Plasma medical Medical Technology for the Repair of $244,479.25 Technologies Living Cells, Tissue and organs. Eye Care and Cure Extra-Ocular Motility Monitor $63,720.71 Corporation (EOMM) Eye Care and Cure I-CORE $53,221.15 Corporation Gary A Flynn Multi-targeted Kinase Inhibitors PhD/Spacefill as Imaging and Therapeutic $27,000.00 Enterprises LLC Agents High Throughout qNPA miRNA Development $41,483.00 $5,419.00 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Genomics, Inc. Project High Throughput Mid Density Platform $73,830.00 $79,962.00 Genomics, Inc Development Project High Throughput qBead Development Project $67,940.00 $38,392.00 Genomics, Inc High Throughput Fusin Gene-SNV Mutation Tests $26,268.50 $28,273.50 Genomics, Inc Development Project High Throughput Pathogen Assay Development $11,131.00 $23,394.00 Genomics, Inc Project High Throughput DLBCL & Cell of Orgin $16,408.50 $8,707.00 Genomics, Inc Development Project High Throughput qSelect Assay Archive $16,026.50 $41,378.50 Genomics, Inc Development Project High Throughput qNPA Platform Technology $71,709.50 $117,348.00 Genomics, Inc Development Project High Throughput Melanoma Screening $20,359.50 Genomics, Inc Development Project High Throughput Radiation Exposure Monitoring $13,797.00 $2,081.00 Genomics, Inc Assay Development Project Hope Medical Treatment of Acute Myocardial $17,542.28 Enterprises, Inc Infarction Hope Medical Treatment of Sickle Cell Disease $3,250.00 $36,907.86 Enterprises, Inc. Recombinant fibrogen & HumaGene Inc $17,985.00 $14,500.00 thrombin InNexus DXL 625 $116,760.00 Biotechnology, Inc. INSYS Therapeutics, Fentanyl Sublingual Spray $244,479.24 Inc INSYS Therapeutics, Dronabinol Oral Solution $244,479.25 Inc Kinetic Muscles Inc Neuro Telerehabilitation System $221,667.65 $22,811.59 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Utilizing the MedApps System MedApps, Inc for Remotely Monitoring $244,479.24 Clinical Drug Therapies MSDx Multiple Biomarkers for Monitoring Sclerosis Multiple Sclerosis Patients - A $82,908.19 $47,063.66 Diagnostics, LLC Window into the Brain Biomarkers for Monitoring MSDx, Inc Multiple Sclerosis Patients - A $74,700.00 window into the Brain Development of molecular PathoGene, LLC assays for the identification and $37,850.50 resistance profiling of MRSA. Engineered Small-Diameter Protein Genomics Artery Grafts Using Synthesized $120,342.50 $124,136.75 Human Elastin Fibrinogen and fibrin Provista Life degradation product lung cancer $137,175.27 Sciences, LLC assay Provista Life Multivariate Breast Cancer $221,153.46 Sciences, LLC Detection and Screening Assay Provista Life Epigenetic Test for Alzheimer's $244,479.25 Sciences, LLC Disease Provista Life Lymphocyte Proliferation Test $180,664.68 Sciences, LLC for Early Alzheimer's Detection Prugen IP Holdings Drug Bioavailability $244,479.25 Inc Enhancement Delivery System Stabilized Chlorine Dioxide for Rowpar Treatment & Prevention of Oral $1,402.50 $3,673.00 Pharmaceuticals, Inc Candidiasis 0.5% Stabilized Chlorine Rowpar Dioxide for the Treatment and $2,881.00 $20,782.50 Pharmaceuticals, Inc Prevention for Gingivitis SALUTARIS SMD-A $244,479.24 MEDICAL Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 DEVICES, INC. Non-invasive boold glucose Sensys Medical Inc monitor for the diagnosis & $244,479.24 treatment of diabetes Southwest Scientific Dietary supplements enhanced Editing & for biofavanoids and antioxidants $2,850.00 $26,200.00 Consulting, LLC to treat human disease Susavion Discovery of Immunotherapeutic $85,997.50 $117,631.00 Biosciences, Inc Drugs Against Viral Infections Kit for noninvasive early Synbuild LLC $11,157.12 detection of pancreatic cancer SYNCARDIA COMPANION 2 DRIVER $54,080.75 SYSTEMS, INC Inline acuator for pMDI Thayer Medical medication delivery in ventilator $66,050.50 $112,333.50 Corporation circuits with 15 mm connection. Pre-Clinical and Clinical Transmed Oncology Development of DNMT1 $70,784.50 Inc inhibiting Compounds Valley Fever Late Stage Valley Fever - Phase $244,479.25 Solutions, Inc. II The Use of Bioelectric Wound Vomaris Care Devices for Improving $244,479.25 Innovations, Inc Healthcare Arkansas $730,294.80 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Mucosal and Cell Targeted RTB BioStrategies, Delivery of Novel Plant Produced $118,994.00 $125,485.25 LC Protein Therapeutics Pacific Vet Pre-clinical Trials for Unique $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Group - USA Competitive Exclusion Treatment Inc. for Gastrointestinal Disease New Biomarker Assays for Stage I Monitoring and Diagnosis of $171,756.22 $69,580.08 Diagnostics, Inc. Ovarian Cancer California $276,141,790.10 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 3-V BROAD SPECTRUM HOST BIOSCIENCES FACTOR DIRECTED $244,479.24 INC ANTIVIRAL THERAPEUTIC Application of continous negative 5iSciences, Inc. external pressure (cNEP) to the $22,834.35 $141,124.00 upper airway APF530- Prevention of A.P. Pharma, Inc Chemotherapy-induced Nausea $244,479.25 and Vomiting Aaken Guided Electrical Stimulation $49,026.40 $36,267.00 Laboratories Aardvark Nasal Irrigation/Aspiration $244,479.24 Medical, Inc. System Ablation Rapid and Simple Cure for Atrial $500.00 $243,979.25 Numerics Inc Fibrillation Acadia Pharmaceuticals Pimavanserin $244,479.25 Inc. Acaduceus Developing Novel Platinum Pharmaceutics based Targeted-Nanoparticles for $12,400.00 $132,500.00 Inc Anti-Cancer Drugs Acaduceus Developing Targeted Probe for $56,150.00 $180,000.00 Pharmeceutics PET imaging of Primary and Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc Metastatic Melanoma Acceleration of Bone Fracture Accelalox Inc. $54,062.50 $132,430.00 Healing Access Scientific The Wand $244,479.25 Inc Gravitas: Gauging Responsiveness With a Accumetrics, Inc $244,479.25 VerifyNow Assay-impact on Thrombosis & Safety Development of and cancer ACEA treatment with Bis(4- $244,479.25 Biosciences Inc. fluorobenzyl)trisulfide (BFBTS) AcelRx Sufentanil NanoTab ™ Patient Pharmaceuticals, Controlled Anagesia (PCA) $244,479.25 Inc System AcelRx Pharmaceuticals, Triazolam/Sufentanil NanoTab ™ $244,479.24